چکیده (انگلیسی):

Sorafenib is slightly absorbed in the gastrointestinal tract due to its poor solubility in water. To improve
its absorption, a novel nanoparticulate formulation-nanomatrix was used in the study. The nanomatrix
was a system prepared from a porous material Sylysia® 350 and a pH sensitive polymer Eudragit®. The
formulations were optimized by orthogonal design (L9(34)) and their bioavailability were evaluated in
rat, comparing to pH-sensitive Eudragit nanoparticles and suspension of sorafenib. In the formulations,
the ratio of sorafenib to Eudragit® S100 was found to be more important determinant of the sorafenib
bioavailability than the ratio of sorafenib to Sylysia® 350. As for the bioavailability, the AUC0–36 h of
sorafenib nanomatrix was 13–33 times to that of sorafenib suspension, but only 16.8% to 40.8% that of
Eudragit® S100 nanoparticles. This may be resulted from the different drug dispersion degree, release
character and bioadhension activity. However, because all the materials used in the nanomatrix formulation
are commonly adjuvant, safe, easy to get and cheap, above all, the nanomatrix formulation can solve
the stability and scaling up problems in the nanoparticles, it had potential to develop into a product in
the future.